or-live. At this time,
the trial is planned to accrue approximately 85 patients. Together
with our previous Phase II study in an elderly AML population, results from
this trial, if successful , will form the clinical basis for a submission to
the FDA of a New Drug Application for Cloretazine (R). ((617) 614-3528 for international
callers), pass code 10864294 at least fifteen minutes before the start of the
call.S. Trials of Cloretazine(R) as
a single agent in previously untreated elderly acute myelogenous leukemia and
high-risk myelodysplastic syndrome, adult and pediatric brain tumors , small
cell lung cancer and chronic lymphocytic leukemia, and in combination with
temozolomide in hematologic malignancies, are also underway.
"We are delighted to have attracted an individual with the talent and
experience of Meghan Fitzgerald to our senior management team" said Alan
Kessman . is developing cancer therapeutics.

neurotoxicity polyneuritis

Aneurysms occur
most commonly in the abdominal aorta, the largest blood vessel in the
abdomen, which carries blood to the abdominal organs and legs. Now, due to advances in
vascular surgery techniques, including the use of angioplasty in patients
who are in good health , this treatment option can be evaluated against a
less invasive option. This new trial, Vion CLI -043, will
focus on elderly patients with de novo poor-risk AML. For additional information
on Vion and its product development programs, visit the Company's Internet web
site at http://www. She will direct new product
planning, business development and corporate strategy. The Company also is
seeking development partners for TAPET(R), its modified Salmonella vector used
to deliver anticancer agents directly to tumors.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

keratosis ayerza

In addition, we would like to
provide our medical colleagues and patients with an inside look at the
advanced techniques our surgeons are able to perform at BWH to treat this
condition. - Trial to Focus on De Novo AML Patients -

NEW HAVEN, Conn.

adie arrhythmia

OR-Live.com Presents: Brigham and Women's Hospital Features Webcast of Minimally Invasive Abdominal Artery Repair Surgery

Abdominal
aortic aneurysms are the 10th leading cause of death for men over the age
of 55., Vion Pharmaceuticals,
Inc.
Elderly poor-risk AML is considered to be AML in patients over sixty years of
age that have certain risk factors affecting the outcome of treatment. Fitzgerald will report to Alan Kessman, Chief Executive Officer of
the company.

aviatophobia ayerza

In preclinical studies, Vion is
also evaluating KS119W, a hypoxia-selective compound from the
sulfonylhydrazine class, and heterocyclic hydrazones.vionpharm.

pectoris apert

Endovascular surgery allows surgeons to minimize
recovery time, reduce hospital stay as well as provide emotional relief for
patients concerned about open surgery."

Visit http://www. In this stratum, a
response rate (CR plus CRp) of 31% was achieved in 107 treated patients. Triapine(R), a
potent inhibitor of a key step in DNA synthesis, is being evaluated in trials
sponsored by the National Cancer Institute .

COMPANY CONTACT: Vion Pharmaceuticals, Inc.
Fitzgerald has also held marketing positions at Merck, Forest Labs, Bayer
Pharmaceutical and Sanofi-Synthelabo.

This news release contains forward-looking statements.

mutism asbestosis

Medical professionals, and the general
public, are invited to log-on to the Webcast on January 20 at 4:30 p."

An aneurysm causes localized widening or enlargement of an artery that may
subsequently rupture causing life-threatening bleeding. eastern time.com."
Prior to joining Vion, Fitzgerald worked at Pfizer Inc from 2001 to early
2006, where she held positions in strategic planning and marketing."

Vion Pharmaceuticals, Inc.

akinetic maltase

EDT
by visiting www."
In October 2005, Vion received a fast track designation from the FDA for
Cloretazine (R) in the treatment of elderly patients with poor-risk AML. Except in special
circumstances in which a duty to update arises under law when prior disclosure
becomes materially misleading in light of subsequent events, Vion does not
intend to update any of these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events . Vion has two
agents in clinical trials: Cloretazine(R), a unique sulfonylhydrazine
alkylating agent, is being evaluated in a Phase III trial in combination with
cytarabine in relapsed acute myelogenous leukemia. Johnson, President + CFO
(203) 498-4210 phone

polyneuritis congenita

(Nasdaq: VION) announced today that it plans to conduct a pivotal Phase
II trial of its anticancer agent Cloretazine (R) in elderly patients with poor-
risk acute myelogenous leukemia (AML). ((617) 801-6888 for
international callers), pass code 53565611 through Tuesday, February 7, 2006. Such statements are
subject to certain risk factors which may cause Vion's plans to differ or
results to vary from those expected, including Vion's ability to secure
external sources of funding to continue its operations, the inability to
access capital and funding on favorable terms, continued operating losses and
the inability to continue operations as a result, its dependence on regulatory
approval for its products, delayed or unfavorable results of drug trials, the
possibility that favorable results of earlier clinical trials are not
predictive of safety and efficacy results in later clinical trials, the need
for additional research and testing, and a variety of other risks set forth
from time to time in Vion 's filings with the Securities and Exchange
Commission, including but not limited to the risks discussed in Vion's Annual
Report on Form 10-K for the year ended December 31, 2004.

polyneuritis pectoris

The Company plans to initiate the pivotal Phase II trial, CLI-043, as soon
as practicable in at least 20 sites in North America and Europe.

polyneuritis hemiplegia

Alan Kessman, Chief Executive Officer, commented, "We believe that this
pivotal Phase II trial, if successful, will establish an additional
registration pathway for Cloretazine (R), to complement the registration effort
already underway in our Phase III trial in relapsed AML .
Alan Kessman, Chief Executive Officer
Howard B.

apert maltase

com . A VNR is available at
http://www.
Elderly de novo poor-risk AML patients are those elderly patients whose poor-
risk AML has not evolved from a prior MDS.

adie asbestosis

or-live.vionpharm. Vion has two
agents in clinical trials: Cloretazine(R), a unique sulfonylhydrazine
alkylating agent, is being evaluated in a Phase III trial in combination with
cytarabine in relapsed acute myelogenous leukemia.

Meghan Fitzgerald Joins Vion's Senior Management Team

In preclinical studies, Vion is
also evaluating KS119W, a hypoxia-selective compound from the
sulfonylhydrazine class, and heterocyclic hydrazones . For additional information
on Vion and its product development programs, visit the Company's Internet web
site at http://www.com .

ayerza alstr

OR-Live. Treatment
for this population of patients represents an unmet medical need.com.

adie apert

com/rams/brw-1284-mkw-q. Food and Drug Administration (FDA)
to discuss data from Vion CLI-033, a Phase II trial in patients with AML and
high-risk myelodysplastic syndromes (MDS ).

This news release contains forward-looking statements. Most
recently, Fitzgerald was Senior Director of Strategic Planning and Business
Development for Pfizer Global Pharmaceuticals , the company's main operating
division. Included among her many industry
accomplishments is her work on developing several international and high-
profile product launch strategies, which helped achieve positioning, pricing,
regulatory and commercial milestones.

avoidant trypanosomiasis

m.
(Click here for details )
Michael Belkin, MD, Chief of BWH's Division of Vascular Surgery will be
performing the surgery with Anthony Whittemore, MD, former Chief of
Vascular Surgery and currently BWH's Chief Medical Officer narrating the
surgical techniques for the viewers. In Stratum A of that trial,
patients over the age of 60 with previously untreated AML and high-risk MDS
are treated with Cloretazine(R) as a single agent.vionpharm.

alagille aspergillosis

ram." He concluded, "All
of us at Vion are focused on getting Cloretazine(R) on the market as soon as
possible.

neurotoxicity trypanosomiasis

"Many patients with a ruptured AAA die before they ever reach a hospital,"
said Whittemore. "We hope that through this Webcast we can raise awareness
about AAA to help prevent arterial rupture. In
addition, Vion has reported a response rate of 49% in a subgroup of 45 elderly
patients with de novo AML. The Company also is
seeking development partners for TAPET(R), its modified Salmonella vector used
to deliver anticancer agents directly to tumors . In this role, she supported executive decision-making related to
business strategies, operations , and tactics, with high-level analyses of
customer groups, industry trends, policy developments, and competitor
activities across all global markets.

amblyopia asbestosis

On Thursday, January 20, 2005, Brigham and
Women's Hospital (BWH) will host a live Webcast for viewers to watch and
learn more about new endovascular repair techniques for an abdominal aortic
aneurysm (AAA), the abnormal dilatation of the major abdominal artery that
causes rupture and severe bleeding., VION PHARMACEUTICALS,
INC . (Nasdaq: VION) announced today that Meghan Fitzgerald has joined its
senior management team as a corporate officer with the title of Chief Business
Officer.

mutism amblyopia

At present, there is no proven non-surgical treatment for AAAs.com/brighamandwomens/1284 now to learn more and
view a program preview . The conference call will also be webcast simultaneously and will be
accessible on Vion's website , http://www.

hemiplegia polyneuritis

According
to Belkin, "Until recently, a large incision, part of an open surgical
approach , was required to treat patients with AAA.
The Company met recently with the U." She added, "CLI-043 is designed to confirm the efficacy and safety
of Cloretazine(R) for elderly patients with de novo poor-risk AML."

Conference Call Notification
Vion will host a conference call today to discuss the clinical development
of Cloretazine(R) at 8:45 a.m.

Vion Pharmaceuticals , Inc. Johnson, President + CFO
(203) 498-4210 phone

At Vion , Fitzgerald will be responsible for the commercialization of the
company's lead anticancer agent , Cloretazine(R). She previously was Worldwide Marketing
Director of Lifecycle Management, where she led a team responsible for
implementing a ten-year lifecycle plan for various pharmaceutical products
including Celebrex, a multi-billion dollar franchise.
Alan Kessman , Chief Executive Officer
Howard B.

mutism polyneuritis

S.
Ann Cahill, Vice President, Clinical Development, commented, "We are
excited about launching this pivotal trial and anticipate rapid patient
accrual. A replay of the call
will be available at (888) 286-8010 in the U.
"I am thrilled to be joining Vion, a wonderful company with exciting
technologies for the treatment of cancer," said Fitzgerald. Except in special
circumstances in which a duty to update arises under law when prior disclosure
becomes materially misleading in light of subsequent events, Vion does not
intend to update any of these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

pectoris hemiplegia

"As Vion prepares for the commercialization of Cloretazine(R),
Meghan's insight and expertise in strategic planning, business development and
marketing will be invaluable. Such statements are
subject to certain risk factors which may cause Vion's plans to differ or
results to vary from those expected, including Vion's ability to secure
external sources of funding to continue its operations, the inability to
access capital and funding on favorable terms, continued operating losses and
the inability to continue operations as a result , its dependence on regulatory
approval for its products, delayed or unfavorable results of drug trials , the
possibility that favorable results of earlier clinical trials are not
predictive of safety and efficacy results in later clinical trials, the need
for additional research and testing, and a variety of other risks set forth
from time to time in Vion's filings with the Securities and Exchange
Commission, including but not limited to the risks discussed in Vion's Annual
Report on Form 10 -K for the year ended December 31, 2004.

alagille alstr

S. NEW HAVEN, Conn. Trials of Cloretazine(R) as
a single agent in previously untreated elderly acute myelogenous leukemia and
high-risk myelodysplastic syndromes , adult and pediatric brain tumors, small
cell lung cancer and chronic lymphocytic leukemia, and in combination with
temozolomide in hematologic malignancies, are also underway. Triapine(R), a
potent inhibitor of a key step in DNA synthesis, is being evaluated in trials
sponsored by the National Cancer Institute.

keratosis amblyopia

Vion Pharmaceuticals Announces Plans to Conduct a Pivotal Phase II Trial of Cloretazine (R) in Elderly Poor-Risk Acute Myelogenous Leukemia

The conference can be accessed
by dialing (800) 561-2731 in the U. is developing cancer therapeutics. "I look forward
to helping guide Cloretazine (R) to market and offering patients, their
families and their physicians a valuable new treatment option for acute
myeloid leukemia, the most common acute leukemia in adults.